AU1668097A - Malaria recombinant poxvirus vaccine - Google Patents

Malaria recombinant poxvirus vaccine

Info

Publication number
AU1668097A
AU1668097A AU16680/97A AU1668097A AU1668097A AU 1668097 A AU1668097 A AU 1668097A AU 16680/97 A AU16680/97 A AU 16680/97A AU 1668097 A AU1668097 A AU 1668097A AU 1668097 A AU1668097 A AU 1668097A
Authority
AU
Australia
Prior art keywords
recombinant poxvirus
poxvirus vaccine
malaria recombinant
malaria
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16680/97A
Inventor
Charles De Taisne
Enzo Paoletti
John A Tine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virogenetics Corp
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Publication of AU1668097A publication Critical patent/AU1668097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU16680/97A 1991-03-20 1997-04-02 Malaria recombinant poxvirus vaccine Abandoned AU1668097A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67218391A 1991-03-20 1991-03-20
US672183 1991-03-20
US85230592A 1992-03-18 1992-03-18
US852305 1992-03-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU16657/92A Division AU674491B2 (en) 1991-03-20 1992-03-19 Recombinant poxvirus malaria vaccine

Publications (1)

Publication Number Publication Date
AU1668097A true AU1668097A (en) 1997-06-12

Family

ID=27100699

Family Applications (3)

Application Number Title Priority Date Filing Date
AU16657/92A Expired AU674491B2 (en) 1991-03-20 1992-03-19 Recombinant poxvirus malaria vaccine
AU16680/97A Abandoned AU1668097A (en) 1991-03-20 1997-04-02 Malaria recombinant poxvirus vaccine
AU16681/97A Expired AU709479B2 (en) 1991-03-20 1997-04-02 Recombinant attentuated canrypox ALVAC virus expression vectors containing heterologous DNA segments encoding malarial gene products

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU16657/92A Expired AU674491B2 (en) 1991-03-20 1992-03-19 Recombinant poxvirus malaria vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU16681/97A Expired AU709479B2 (en) 1991-03-20 1997-04-02 Recombinant attentuated canrypox ALVAC virus expression vectors containing heterologous DNA segments encoding malarial gene products

Country Status (5)

Country Link
EP (1) EP0575544A4 (en)
JP (1) JPH06505397A (en)
AU (3) AU674491B2 (en)
CA (1) CA2106464A1 (en)
WO (1) WO1992016616A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217898A (en) * 1988-05-02 1993-06-08 The United States Of America As Represented By The Secretary Of Health And Human Services Expression of the P. falciparum transmission-blocking antigen in yeast
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
DE19640817A1 (en) * 1996-10-02 1998-05-14 Hermann Prof Dr Bujard Recombinant manufacturing process for a complete malaria antigen gp190 / MSP 1
AU3910097A (en) * 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US7198791B2 (en) 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
MY175250A (en) 2009-05-05 2020-06-17 Cadila Healthcare Ltd Combined measles-malaria vaccine
CA2935341A1 (en) * 2013-12-30 2015-07-09 V-Core Technologies, Inc. Poxvirus-plasmodium recombinants, compositions containing such recombinants, uses thereof, and methods of making and using same
WO2018237339A1 (en) * 2017-06-22 2018-12-27 The Government Of The United States Of America As Represented By The Secretary Of The Army Nyvac-based plasmodium malaria vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
AU613970B2 (en) * 1987-10-09 1991-08-15 Motorola, Inc. Radio arrangement having two radios sharing circuitry
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
WO1990001549A2 (en) * 1988-08-12 1990-02-22 Trustees Of Dartmouth College Gene encoding protein antigens of plasmodium falciparum
IE71643B1 (en) * 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper
AU1588092A (en) * 1991-02-22 1992-09-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Transmission blocking vaccine against malaria
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
CA2110489A1 (en) * 1991-06-14 1992-12-23 Enzo Paoletti Immunodeficiency virus recombinant poxvirus vaccine

Also Published As

Publication number Publication date
WO1992016616A1 (en) 1992-10-01
AU1668197A (en) 1997-06-12
CA2106464A1 (en) 1992-09-21
AU1665792A (en) 1992-10-21
AU674491B2 (en) 1997-01-02
AU709479B2 (en) 1999-08-26
EP0575544A1 (en) 1993-12-29
JPH06505397A (en) 1994-06-23
EP0575544A4 (en) 1997-05-21

Similar Documents

Publication Publication Date Title
EP0717636A4 (en) Malaria recombinant poxvirus vaccine
GB9303023D0 (en) Flavivirus recombinant poxvirus vaccine
AU3601689A (en) Recombinant coccidiosis vaccines
AU2838489A (en) Live vaccine against coccidosis utilizingcoccidial sporozoites
GB9105992D0 (en) Vaccine
AU4325089A (en) Viral vaccines
IT1241119B (en) RECOMBINANT HERPESVIRUS POXVIRUS VACCINE
AU3247093A (en) Flea midgut-supernatant vaccines
AU1257092A (en) Interferon sensitive recombinant poxvirus vaccine
AU5989894A (en) Live coccidiosis vaccine
AU1588092A (en) Transmission blocking vaccine against malaria
AU628149B2 (en) Coccidiosis vaccine
AU7617791A (en) Recombinant immunocastration vaccine
AU667811B2 (en) Coccidiosis vaccines
AU1668097A (en) Malaria recombinant poxvirus vaccine
IL101639A0 (en) Recombinant influenza vaccines
AU1118888A (en) Conjugate malaria vaccine
AU6777490A (en) Malaria vaccine
AU6715094A (en) Recombinant vaccine
AU2347692A (en) Recombinant viral vaccine
AU635036B2 (en) Recombinant avipoxvirus
AU1229492A (en) Live vaccine against colibacillosis
AU2775692A (en) Recombinant influenza virus vaccine compositions
AU5450590A (en) Malaria vaccine
AU4489896A (en) Avian recombinant live vaccine